Clinical Trials at Waverly Hematology Oncology

Waverly Hematology Oncology is able to offer patients cutting edge therapy by participating in clinical trials. Patients will have access to state-of-the-art treatments normally found at large academic facilities while receiving personalized, community-based care.  Waverly Hematology Oncology is the only Triangle site of the SCOR (Southeast Clinical Oncology Research, Inc), a consortium of 22 practices in 5 states. Today’s clinical trial treatment may become tomorrow’s standard of care.

Please contact Gena Boyd for further information:
919-233-8585 or gboyd@waverlyhemeonc.com

ALL CANCERS:
 
Molecular Analysis for Therapy Choice (MATCH / EAY131)
Sponsor: National Cancer Institute
Status: ENROLLING
 
BREAST CANCER:
 
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (E5103)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
 
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment. The TAILORx Trial (ECOG PACCT-1)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
 
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Paclitaxel in Combination with Reparixin Compared to Paclitaxel Alone as Front-Line Therapy for Metastatic Triple-Negative Breast Cancer (FRIDA / Rep0114)
Sponsor: Dompe Pharmaceuticals
Status: ENROLLING
 
A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP-B49)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
 
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamozifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (NSABP-B42)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
 
A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC (SPI-POZ-201)
Sponsor: Spectrum Pharmaceuticals
Status: ENROLLING
 
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: "A Clinical Trial RX for Positive Node, Endocrine Responsovie Breast Cancer" (SWOG 1007)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
 
Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer (SWOG 1105)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
 
Randomized Trial to Evaluate SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCER Patients Receiving Docetaxel and Cyclophosphomide (TC) (RECOVER / SPI-GCF-302)
Sponsor: Spectrum Pharmaceuticals
Status: ENROLLING
 
Randomized Phase III Trials Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL / A011401)
Sponsor: National Cancer Institute
Status: ENROLLING
 
Asprin for Breast Cancer Study (ABC study)
Sponsor: ALLIANCE
Status: ENROLLING
 
A Randomized Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer (Monarch E / NASBP B-58)
Sponsor: Eli Lilly and Company and its representatives
Status: ENROLLING
 
CHRONIC MYELOID LEUKEMIA (CML):
 
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase:  The 5-Year Prospective Cohort Study (SIMPLICITY / CA180-330)
Sponsor: Bristol-Myers Squibb (BMS)
Status: Active but not currently accepting new participants
 
COLON CANCER:
 
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO / C-13)
Sponsor: NSABP Foundation
Status: Active but not currently accepting new participants
 
HOT FLASHES:
 
A Phase III, Controlled Trial of Oxybutynin in the Management of Hot Flashes
Sponsor: ACCRU
Status: ENROLLING
 
IRON STUDIES:
 
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-Center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety or Injectafer (Ferric Carboxymaltose Injection) (IRON CLAD / 1VIT14039)
Sponsor: Luitpold Pharmaceuticals
Status: Active but not currently accepting new participants
 
LUNG CANCER:
 
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-Small Cell Lung Cancer Subjects (KEYNOTE-407)
Sponsor: Merck
Status: Active but not currently accepting new participants
 
A Randomized, Double-Blind, Phase III Study of Platinum + Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects (KEYNOTE-189)
Sponsor: Merck
Status: Active but not currently accepting new participants
 
MULTIPLE MYELOMA:
 
A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles (the "CoMMpass Study" / MMRF-11-001)
Sponsor: Multiple Myeloma Research Foundation
Status: Active but not currently accepting new participants
 
OTHER:
 
ESSENTIAL THROMBOCYTHEMIA:
 
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who are Resistant to or Intolerant of Hydroxyurea
Sponsor: Incyte Corporation
Status: ENROLLING
 
CHRONIC LYMPHOCYTIC LEUKEMIA:
 
A Disease Registry for Patients with Chronic Lymphocytic Leukemia
Sponsor: Pharmacyclics LLC
Status: ENROLLING